Page last updated: 2024-09-03
nnc 112 and naxagolide
nnc 112 has been researched along with naxagolide in 1 studies
Compound Research Comparison
| Studies (nnc 112) | Trials (nnc 112) | Recent Studies (post-2010) (nnc 112) | Studies (naxagolide) | Trials (naxagolide) | Recent Studies (post-2010) (naxagolide) |
|---|---|---|---|---|---|
| 32 | 3 | 7 | 159 | 8 | 49 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Alexoff, D; Carter, P; Fowler, JS; Kang, Y; Kim, D; Kim, SW; King, P; Logan, J; Muench, L; Shea, C; Skolnick, P; Volkow, ND | 1 |
Other Studies
1 other study(ies) available for nnc 112 and naxagolide
| Article | Year |
|---|---|
Therapeutic doses of buspirone block D3 receptors in the living primate brain.
Topics: Administration, Oral; Animals; Anti-Anxiety Agents; Benzazepines; Benzofurans; Buspirone; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Female; Functional Neuroimaging; Globus Pallidus; Injections, Intramuscular; Mesencephalon; Oxazines; Papio anubis; Positron-Emission Tomography; Raclopride; Radioligand Assay; Receptors, Dopamine D3 | 2014 |